You have reached the number on the scale you were working toward and the first feeling is relief. The second feeling arrives about a week later when you realize nobody told you what comes next. Do you keep taking the full dose forever? Can the dose come down? What happens if you stop entirely? Most GLP-1 programs go quiet at exactly this moment because the moment is bad for their revenue and good for yours. This guide is the conversation about maintenance that a dose-based business has no reason to have.
- The right maintenance dose is the lowest dose that holds your weight and your metabolic markers rather than the highest dose you tolerated during the loss phase.
- The trial evidence is clear about stopping abruptly: in SURMOUNT-4, participants who stopped regained roughly half of what they lost while the group that continued kept losing.
- Step-downs often work and attempting one under monitoring costs little if it fails.
- Every dose change shows up directly in your pharmacy bill because the medicine is billed at the pharmacy's own price with nothing added by us.
- Our fee is a flat $299 a month regardless of dose, so nobody here earns more from keeping the dose high.
We write this from the clinical side of the maintenance question because it is the moment our patients bring up most often and because the answer separates measurement-based care from dose-based commerce more cleanly than any other moment in treatment.
The direct answer
There is no universal maintenance dose for tirzepatide. The clinical task after goal weight is to find the lowest dose that holds the result and that floor is different for every body. Some patients hold their result on the dose that got them there. Some step down successfully and save money each month. Some need the full dose indefinitely and that is a fact to be discovered rather than assumed in either direction. The process that finds it is unglamorous: a planned step-down attempt or a planned hold, quarterly labs, honest weigh-ins and a named clinician who reads the trend and answers the messages.
What is not the answer is silence and silence is what most patients get.
What the evidence says about stopping
The clearest data on the maintenance question comes from SURMOUNT-4, published in JAMA in 2024. Adults with obesity or overweight received tirzepatide for 36 weeks and lost an average of about 21% of their body weight. They were then randomized to continue or switch to placebo for another 52 weeks. The group that continued lost a little more. The group that stopped regained roughly half of what they had lost and their blood pressure and lipid improvements faded with the weight.
Read that result honestly and it says two things at once. First, tirzepatide is a treatment rather than a cure and the systems that defended your old weight do not retire because the scale moved. Second, abrupt discontinuation is the worst of the available options because it surrenders the result with no plan. What the trial did not test is the third option that real clinicians use every week: a deliberate, monitored step-down to find your personal floor. That experiment runs in clinics rather than in trials and it is where your maintenance answer comes from.
The maintenance options
what each costs and what it risks
| Approach | What happens | Who it suits |
|---|---|---|
| Abrupt stop | Weight regain in most trial participants and metabolic gains fading | Almost nobody, though it is the default when care ends |
| Hold the full dose | Result typically holds and the pharmacy bill stays at the higher dose tier | Patients whose labs or history argue for it |
| Planned step-down | Dose drops and weight and labs are watched quarterly until the floor is found | Most patients who have reached goal and stabilized |
| Stop with a plan | Structured taper with nutrition and training support and scheduled rechecks | Patients with strong maintenance habits and clinician support |
Notice that the table has no row for guesswork. Every row except the first involves a clinician watching data and that is the entire point.
How a careful step-down actually works
A step-down is not simply taking a smaller dose and hoping. It is a protocol and we will describe the shape of it so you can recognize whether the care you are receiving resembles it.
The first requirement is stability. Nobody steps down while still losing or while markers are moving. The prerequisite is a stable weight for several weeks and a Biomarker Audit showing where you stand: HbA1c, insulin markers, lipids including ApoB, inflammation and the full hormone and thyroid panels. A patient whose HbA1c fell from 6.1 to 5.5 on treatment has a marker to protect and the maintenance dose is chosen partly to protect that marker rather than only the scale.
The second requirement is a defined observation window. A dose reduction is followed for eight to twelve weeks with weigh-ins and a repeat look at the numbers. Weight can drift a few pounds without meaning anything but a trend across two months means something. If the result holds at the lower dose the conversation about another step happens at the next quarterly audit. If weight or markers start climbing the dose returns to the previous level without drama because the attempt cost a few weeks and the information it bought is permanent.
The third requirement is honesty about the pharmacy bill. Because your medication is billed by your pharmacy at the pharmacy's own price every step down shows up in your monthly cost automatically. Lilly publishes self-pay vial pricing through LillyDirect that varies by dose, commonly reported between $299 and $449 a month as of 2026, with lower doses at the lower end of the range. We set nothing on that price and add nothing to it. One flat fee for the doctor. Zero markup on the medicine. When your dose drops your bill drops and that is exactly as it should be.
The goal is never the biggest dose you can tolerate. It is the least medicine that gets you the most result and it stays that way after goal weight. A dose you no longer need is a side effect load and a bill you should not be carrying.
Why the industry prefers not to have this conversation
It is worth naming the structure underneath the silence because you are a careful buyer and you deserve the map. A program that earns its margin on the medication has a reason to keep your dose where it is and the maintenance phase is where that reason does its quietest work. The loss phase has energy and urgency. The maintenance phase is long, flat and cheap to serve and a dose you no longer need is pure margin to a business that marks the medicine up.
We built the membership so that this moment cannot corrupt the advice. The fee is $299 a month, flat, with no tiers and no dose upcharge. Medication is billed separately by your pharmacy at its own price with zero markup, no molecule upcharge and no dose upcharge from us. If your clinician determines that 5 milligrams holds your result as well as 12.5 did, our revenue does not move and your pharmacy bill falls. We make money when you get healthier, not when your dose gets stronger. That sentence is a business model before it is a slogan and maintenance dosing is where it pays you back.
There is a second quiet benefit. Because the Biomarker Audit repeats every 90 days the maintenance decision is never made from memory. The clinician who reviews your step-down is looking at four panels a year and can see the HbA1c trend, the ApoB trend and the weight trend together, which is the only context in which a dose decision is honest.
What the year looks like, in money
Run the maintenance year as an arithmetic problem so the stakes are concrete. The membership is $299 a month or $3,588 for a full year, with the first charge of $598 covering the first two months combined. On top of that comes the pharmacy bill for the medication at whatever dose your clinician has landed on, at the pharmacy's own published price. If a successful step-down saves $100 a month on the vial the maintenance year costs $1,200 less than it would have, every year, for as long as the result holds. Over a five-year hold that is $6,000 that stayed in your pocket because someone had the motive to look for the floor.
No honest clinician can promise the step-down succeeds. What we can promise is that the attempt is made with labs rather than with guesses and that nobody here loses money when it succeeds.
When holding the full dose is the right answer
Balance deserves an honest hearing because a step-down is not right for everyone and pretending otherwise would be the mirror image of the escalation reflex. Patients whose baseline included type 2 diabetes or significant insulin resistance, whose HbA1c sits close to the top of where your clinician wants it or whose history shows rapid regain after past diets may be better served holding the dose that produced the result. The decision follows the labs. If your quarterly audit shows markers that are excellent but fragile, holding is a clinical answer and a wise one.
The patients who should absolutely not attempt a step-down are the ones without any monitoring plan behind it. A dose cut without scheduled weigh-ins, without a clinician reading the trend and without a threshold for going back up is not a maintenance strategy. It is a lapse with a plan-shaped name.
If you are approaching goal weight and want to see how the maintenance conversation fits the wider program, read the definitive guide to Cardiometabolic Optimization. For what to do when the scale stalls mid-treatment, Weight loss plateau on a GLP-1 covers it in depth and Branded GLP-1 pass-through prices, explained shows where each published self-pay price sits today.
FAQ
What is the right tirzepatide maintenance dose after reaching goal weight?
There is no single right dose. The clinical goal is the lowest dose that holds your weight and your metabolic markers where you and your clinician want them. Some patients hold their result on the dose that got them there and others step down successfully. The way to find out is planned monitoring rather than guesswork.
Do you have to stay on tirzepatide forever?
Obesity is treated as a chronic condition and the trial evidence shows weight regain when the medication stops. That does not mean every person needs the drug forever. It means stopping should be a deliberate clinical decision made with follow-up labs and a plan, never a quiet lapse.
What happens if I stop tirzepatide completely?
In the SURMOUNT-4 extension, participants who stopped tirzepatide after 36 weeks regained roughly half the weight they had lost over the following months while the group that continued kept losing. Appetite returns and the systems that defended your old weight reassert themselves. Regain is common but not universal and it is manageable when it is watched.
Can I lower my tirzepatide dose after reaching my goal?
Often yes and it is worth attempting under supervision. A step-down approach with quarterly labs and weigh-ins can identify the dose floor where your weight, HbA1c and other markers hold. If a lower dose loses the result the dose goes back up and you have lost little except a few weeks.
How much does tirzepatide cost at a maintenance dose?
Lilly publishes self-pay vial pricing through LillyDirect that varies by dose, commonly reported between $299 and $449 a month as of 2026, with lower doses at the lower end of the range. Your pharmacy bills that price directly and we add nothing to it, so a step down in dose lowers your pharmacy bill automatically.
Does GoodLife Health profit if my dose stays high?
No. The membership is a flat $299 a month and medication is billed separately by your pharmacy at the pharmacy's own price with zero markup, no molecule upcharge and no dose upcharge. When your dose goes down your pharmacy bill goes down and our fee does not change.
Related Reading
- Weight loss plateau on a GLP-1: what actually helps
- Branded GLP-1 pass-through prices, explained
- The definitive guide to Cardiometabolic Optimization
References
- Tirzepatide for Weight Reduction vs Placebo in Adults With Obesity or Overweight and Type 2 Diabetes (SURMOUNT-4 extension, JAMA). 2024. jamanetwork.com/journals/jama/fullarticle/2811688
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Zepbound Self Pay Journey Program, LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings